Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290025 | 0.85 | KCNA5 (0.50) | CA1NQO2KCNA5 | |
| SCHEMBL6292867 | 0.83 | CYP3A4 (0.52) | CYP3A4CA1CA2DRD2TDP1 | |
| Hydrochloric Acid SCHEMBL8120313 | 0.83 | CYP3A4 (0.43) | CYP3A4CA1CA2DRD2MAPT | |
| SCHEMBL6292887 | 0.83 | CYP3A4 (0.53) | CYP3A4CA1CA2DRD2TDP1 | |
| SCHEMBL6292866 | 0.81 | DRD2 (0.41) | CYP3A4CA1CA2DRD2TDP1 | |
| SCHEMBL9118035 | 0.80 | CYP3A4 (0.60) | CYP3A4CA1CA2DRD2TDP1 | |
| SCHEMBL14102774 | 0.79 | CYP3A4 (0.75) | CYP3A4CA1CA2TDP1MAPT | |
| SCHEMBL24521598 | 0.78 | CYP3A4 (0.58) | CYP3A4CA1CA2DRD2TDP1 | |
| SCHEMBL8395672 | 0.78 | HMGB1 (0.55) | CYP3A4CA1CA2 | |
| SCHEMBL7603561 | 0.77 | CYP3A4 (0.52) | CYP3A4CA1CA2DRD2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | CYP3A4 853/4885CA1 470/4885CA2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.